by Mark Chiang

马克·蒋

Share To

分享到

The European Commission has granted approval for Tevimbra (tislelizumab), developed by BeOne Medicines, to be used in combination with gemcitabine and cisplatin for the treatment of nasopharyngeal carcinoma (NPC). This decision allows the use of Tevimbra as part of a therapeutic regimen targeting adult patients diagnosed with this specific type of cancer..

欧盟委员会已批准百济神州开发的Tevimbra（替雷利珠单抗）与吉西他滨和顺铂联合使用，用于治疗鼻咽癌（NPC）。这一决定允许将Tevimbra作为针对成年患者的特定类型癌症治疗方案的一部分。

Nasopharyngeal carcinoma is a rare form of cancer that originates in the nasopharynx, located behind the nose and above the back of the throat. The approved combination therapy includes Tevimbra, an anti-PD-1 monoclonal antibody, alongside gemcitabine and cisplatin, which are established chemotherapy agents.

鼻咽癌是一种罕见的癌症，起源于位于鼻子后方和喉咙后上方的鼻咽。获批的联合疗法包括抗PD-1单克隆抗体Tevimbra，以及已确立的化疗药物吉西他滨和顺铂。

The approval follows a review process by regulatory authorities assessing its safety and efficacy in treating NPC..

该批准是在监管机构对其治疗鼻咽癌的安全性和有效性进行审查程序后作出的。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

Date: July 11, 2025

日期：2025年7月11日

Related posts:

相关文章:

Google Patents: Pharmaceutical Researchers Refine Searches with Date and Status Filters

谷歌专利：医药研究人员通过日期和状态过滤器优化搜索

Cefiderocol Study Finds Different Common Adverse Effects Than Listed in Prescribing Information

头孢地罗研究发现与处方信息中列出的常见不良反应不同

USP Opens Advanced Technology Laboratory in Maryland to Enhance Medicine Production and Supply Chain Security

美国药典在马里兰州开设先进技术实验室，以增强药品生产和供应链安全。

BioNTech and Bristol Myers Squibb Partner on PD-L1xVEGF-A Antibody for Tumor Treatment

BioNTech与百时美施贵宝合作开发PD-L1xVEGF-A抗体用于肿瘤治疗

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 版权所有。与我们合作：

[email protected]

[email protected]

Author

作者

Mark Chiang

马克·江

Related Post

相关帖子

News Flash

新闻快讯

MUSC Researchers Develop Immunotherapy to Disrupt Signaling Loop in Leukemia Cells

MUSC研究人员开发出破坏白血病细胞信号环路的免疫疗法

2025-07-14

2025年7月14日